Balixafortide

Drug Profile

Balixafortide

Alternative Names: POL-6326

Latest Information Update: 23 Jun 2016

Price : $50

At a glance

  • Originator Polyphor
  • Class Antineoplastics; Cyclic peptides; Epitopes; Peptidomimetics
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma; Cancer; Coronary artery restenosis; Inflammation; Stem cell mobilisation; Wounds

Highest Development Phases

  • Phase II Myocardial infarction; Stem cell mobilisation
  • Phase I Breast cancer; Solid tumours; Wounds
  • No development reported Coronary artery restenosis; Inflammation

Most Recent Events

  • 09 Jun 2016 Polyphor completes the phase II CATCH-AMI trial in Myocardial infarction in Austria, Germany, Hungary, Poland, Norway, Croatia and United Kingdom (NCT01905475; EudraCT 2012-003229-91)
  • 17 Aug 2015 No recent reports on development identified - Preclinical for Inflammation in Switzerland (IV)
  • 17 Aug 2015 No recent reports on development identified - Preclinical for Coronary artery restenosis in Switzerland (Intracoronary)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top